MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS

Daiichi Sankyo, Inc. announced today that the United States Food and Drug Administration (FDA) has approved WelChol(R) (colesevelam HCl) Tablets as the first LDL cholesterol lowering medication also indicated for improving glycemic control in adults with type 2 diabetes mellitus (DM) in combination with metformin, sulfonylureas, or insulin, when these agents are used alone or in combination with other anti-diabetic agents.

The ADA estimates that 20.8 million people in the United States have diabetes and more than 90% of these have type 2 diabetes. People with diabetes face significantly higher risk of developing cardiovascular disease. It is estimated that approximately half of all Americans have elevated blood cholesterol levels that can negatively impact their health and quality of life. According to a recent Harris Interactive Survey, approximately 29% of adults previously diagnosed with hypercholesterolemia have also been diagnosed with diabetes. Given the prevalence of diabetes and high LDL cholesterol, a medication that can help lower both A1C and LDL cholesterol can be beneficial for many patients. Welchol is a new option that addresses these two chronic health conditions and provides physicians with a different therapeutic approach for treating patients with type 2 diabetes.

For more information, please visit www.dsus.com. SATELLITE FEED: Friday, January 18th, 2008 6:30 PM - 6:45 PM ET Galaxy 25 C-Band Transponder 14 Downlink Freq. 3980 Horizontal

Preview and access this video on Pathfire DMG: Slug # 29711

Search within the PR Newswire or MultiVu section by story ID # 29711 or by headline

For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com

NEWS: WelChol Receives FDA Approval To Reduce Blood Glucose in Adults with Type 2 Diabetes

FORMAT: B-roll and Soundbites.

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/29711/press.html

    SOUNDBITES:
    * Dr. Ronald B. Goldberg, Professor of Medicine and Professor,
      Biochemistry and Molecular Biology at the University of Miami and the
      Associate Director of the Diabetes Research Institute

    B-ROLL INCLUDES:
    * Doctor/Patient footage
    * Patient lifestyle & footage
    * Product shots/manufacturing footage
    * Daiichi Sankyo exteriors

VIDEO PROVIDED BY: Daiichi Sankyo

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3